FR2811591B1 - Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques - Google Patents

Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques

Info

Publication number
FR2811591B1
FR2811591B1 FR0009169A FR0009169A FR2811591B1 FR 2811591 B1 FR2811591 B1 FR 2811591B1 FR 0009169 A FR0009169 A FR 0009169A FR 0009169 A FR0009169 A FR 0009169A FR 2811591 B1 FR2811591 B1 FR 2811591B1
Authority
FR
France
Prior art keywords
substance
treated
enclosure
alteration
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0009169A
Other languages
English (en)
Other versions
FR2811591A1 (fr
Inventor
Jacques Benveniste
Didier Guillonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digibio SA
Original Assignee
Digibio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digibio SA filed Critical Digibio SA
Priority to FR0009169A priority Critical patent/FR2811591B1/fr
Priority to US10/332,609 priority patent/US20040038937A1/en
Priority to EP01984149A priority patent/EP1322378A1/fr
Priority to PCT/FR2001/002172 priority patent/WO2002004067A1/fr
Priority to AU2002218753A priority patent/AU2002218753A1/en
Publication of FR2811591A1 publication Critical patent/FR2811591A1/fr
Application granted granted Critical
Publication of FR2811591B1 publication Critical patent/FR2811591B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00—Details not covered by any other group of this subclass
    • G01N37/005—Measurement methods not based on established scientific theories
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/16—Screening or neutralising undesirable influences from or using, atmospheric or terrestrial radiation or fields
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)

Abstract

La pr esente invention concerne un proc ed e appliqu e à une substance trait ee pour pr esenter une activit e biologique, par exemple une activit e coagulante ou anticoagulante. La substance trait ee a et e obtenue, à partir d'une substance source poss edant l'activit e biologique, au terme d'un traitement tel que la substance trait ee ne contient pas de mol ecule de la substance source en quantit e significative. Le traitement peut notamment consister à mettre en oeuvre un proc ed e de haute dilution de même nature que celui utilis e pour produire des solutions ou des granules hom eopathiques. Le proc ed e est conçu pour prot eger la substance trait ee des influences externes qu'elle subit et est caract eris e en ce qu'il comprend l' etape de placer la substance trait ee dans une enceinte (19), à l'abri des champs electromagn etiques. L'enceinte (19) est entour ee d'un blindage (19a) magn etique r ealis e notamment en fer doux ou en mum etal.
FR0009169A 2000-07-12 2000-07-12 Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques Expired - Lifetime FR2811591B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0009169A FR2811591B1 (fr) 2000-07-12 2000-07-12 Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques
US10/332,609 US20040038937A1 (en) 2000-07-12 2001-07-05 Method and device for avoiding alteration of a substance having biological activities
EP01984149A EP1322378A1 (fr) 2000-07-12 2001-07-05 Procede et dispositif pour eviter l'alteration d'une substance ayant des activites biologiques
PCT/FR2001/002172 WO2002004067A1 (fr) 2000-07-12 2001-07-05 Procede et dispositif pour eviter l'alteration d'une substance ayant des activites biologiques
AU2002218753A AU2002218753A1 (en) 2000-07-12 2001-07-05 Method and device for avoiding alteration of a substance having biologicaal activities

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0009169A FR2811591B1 (fr) 2000-07-12 2000-07-12 Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques

Publications (2)

Publication Number Publication Date
FR2811591A1 FR2811591A1 (fr) 2002-01-18
FR2811591B1 true FR2811591B1 (fr) 2014-11-07

Family

ID=8852446

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0009169A Expired - Lifetime FR2811591B1 (fr) 2000-07-12 2000-07-12 Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques

Country Status (5)

Country Link
US (1) US20040038937A1 (fr)
EP (1) EP1322378A1 (fr)
AU (1) AU2002218753A1 (fr)
FR (1) FR2811591B1 (fr)
WO (1) WO2002004067A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894673B1 (fr) * 2005-12-14 2014-10-31 Luc Montagnier Procede de caracterisation d'un element biochimique presentant une activite biologique,par analyses des signaux electromagnetiques de basses frequences
FR2902883B1 (fr) * 2006-06-22 2008-09-12 Nanectis Biotechnologies Procede de detection de microorganisme au sein d'un echantillon
US8405379B1 (en) 2008-09-18 2013-03-26 Luc Montagnier System and method for the analysis of DNA sequences in biological fluids
EP2402057A4 (fr) * 2009-11-20 2012-02-22 Etory Ltd Procédé de télétransmission d'un signal porteur d'informations relatives à l'énergie à partir d'objets animés et inanimés et convertisseur de signaux porteurs d'informations relatives à l'énergie
WO2015082964A1 (fr) * 2013-12-06 2015-06-11 Germanov Evgenij Pavlovich Dispositif de transmission à distance d'une grandeur représentant un rayonnement électromagnétique émis par un matériau, et procédés permettant de faire fonctionner ledit dispositif
US12107275B2 (en) * 2018-09-04 2024-10-01 Daramic, Llc Lead acid battery separators, separator and electrode assemblies, batteries, systems, and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2449951A1 (fr) * 1979-02-23 1980-09-19 Ohresser Gerard Dispositif d'adsorption des rayonnements
US4287543A (en) * 1979-12-31 1981-09-01 American Optical Corporation Tape head mount
FR2634381B1 (fr) * 1988-07-25 1990-09-07 Morez Jean Bernard Procede pour la fabrication de medicaments homeopathiques en une seule operation quelque soit la dilution choisie
IT1290779B1 (it) * 1995-06-26 1998-12-10 Antonio Sacchetti Procedimento per il potenziamento delle attivita' terapeutiche di sostanze naturali (vitamine, minerali, erbe, fitopreparati, alimenti)
DE19713821A1 (de) * 1997-04-03 1998-10-15 Ralf Riba Zelt zum Schutz vor elektromagnetischer Strahlung
FR2783606B1 (fr) * 1998-09-23 2000-11-24 Digibio Procede et systeme pour produire une substance ou un signal ayant un effet coagulant ou anticoagulant. applications therapeutiques de ladite substance ou dudit signal
FR2783605A1 (fr) * 1998-09-23 2000-03-24 Digibio Procede, systeme et dispositif pour produire a partir d'une substance des signaux, notamment des signaux electriques, caracteristiques de l'activite biologique et/ou chimique de ladite substance

Also Published As

Publication number Publication date
WO2002004067A1 (fr) 2002-01-17
EP1322378A1 (fr) 2003-07-02
FR2811591A1 (fr) 2002-01-18
AU2002218753A1 (en) 2002-01-21
US20040038937A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
Wolbers et al. Apoptotic cell death kinetics in vitro depend on the cell types and the inducers used
Adams Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains.
Robillard et al. High resolution nuclear magnetic resonance study of the histidine—aspartate hydrogen bond in chymotrypsin and chymotrypsinogen
DE69027024T2 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
FR2811591B1 (fr) Procede et dispositif pour eviter l'alteration d'une subtance ayant des activites biologiques
Harris et al. Electron paramagnetic resonance and difference ultraviolet studies of Mn2+ binding to serum transferrin
ATE161191T1 (de) Stabilisierte antikörper
NO960733L (no) Fremgangsmåte ved behandling av avfallsvannslam inneholdende minst et metall
DE69926400D1 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
Doering et al. Chemical blocking of zinc ions in CNS increases neuronal damage following traumatic brain injury (TBI) in mice
Valensin et al. Exploring the reactions of β-Amyloid (Aβ) peptide 1–28 with AlIII and FeIII Ions
Bouteille et al. [1] Techniques of localization of proteins and nucleoproteins in the cell nucleus by high resolution autoradiography and cytochemistry
ATE142020T1 (de) Verfahren zur haaranalyse
DE60104401D1 (de) Verfahren zur behandlung von einem organischen anteil enthaltendem festen abfall
Christensen et al. Retrograde tracing of zinc-containing neurons by selenide ions: a survey of seven selenium compounds.
Pirici et al. Matrix metalloproteinase‐9 expression in the nuclear compartment of neurons and glial cells in aging and stroke
Karreman et al. Discovery of a new RNA‐containing nuclear structure in UVC‐induced apoptotic cells by integrated laser electron microscopy
PT927195E (pt) Processo para o fabrico de um medicamento contendo plasmoproteina
DE69609054T2 (de) Ein prozess für die herstellung von faktor ix biologischen ursprungs
Moini et al. Buyid silk and the tale of Bibi Shahrbanu: identification of biomarkers of artificial aging (forgery) of silk
AU7264491A (en) Monoclonal antibody against complexed and noncomplexed complexing agents for removing heavy metals from aqueous solutions and for analysis
Wilson et al. Tissue dispersion and flow cytometry for the cellular analysis of wound healing
Heusinger et al. Sensory deafferentation modulates and redistributes neurocan in the rat auditory brainstem
Lin et al. The activity, distribution, and colocalization of cathepsin K and matrix metalloproteases in intact and eroded dentin
Adelman et al. Do organic substances act as a degradable binding matrix in calcium oxalate kidney stones?

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070330

RN Application for restoration
FC Decision of inpi director general to approve request for restoration
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19